Compare HMY & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HMY | MEDP |
|---|---|---|
| Founded | 1950 | 1992 |
| Country | South Africa | United States |
| Employees | 34350 | N/A |
| Industry | Precious Metals | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 11.7B |
| IPO Year | N/A | 2016 |
| Metric | HMY | MEDP |
|---|---|---|
| Price | $15.71 | $417.53 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 12 |
| Target Price | $16.00 | ★ $473.17 |
| AVG Volume (30 Days) | ★ 4.8M | 451.2K |
| Earning Date | 02-04-2016 | 04-22-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | N/A | ★ 20.98 |
| EPS | N/A | ★ 4.28 |
| Revenue | N/A | N/A |
| Revenue This Year | $37.43 | $13.19 |
| Revenue Next Year | $27.44 | $7.75 |
| P/E Ratio | ★ $15.60 | $96.40 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.03 | $284.10 |
| 52 Week High | $26.04 | $628.92 |
| Indicator | HMY | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 43.54 | 36.68 |
| Support Level | $14.89 | $382.68 |
| Resistance Level | $16.21 | $485.13 |
| Average True Range (ATR) | 0.56 | 17.73 |
| MACD | -0.14 | -11.40 |
| Stochastic Oscillator | 16.01 | 28.40 |
Harmony Gold Mining Co Ltd is engaged in gold mining and related activities, including exploration, extraction, and processing. The group's primary product is gold bullion, produced at operations in South Africa and Papua New Guinea. Gold byproducts include uranium and silver. Strategic projects such as the Wafi-Golpu Project in the New Guinea Mobile Belt, the Eva Copper Project in the Mt Isa Inlier, Queensland, Australia, and the MAC Copper acquisition position the company as a gold-copper producer. The company operates across South Africa, Papua New Guinea, and Australia.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.